JNJ - Johnson & Johnson
| Previous Close | 130.60 |
| Open | 131.70 |
| Bid | 131.53 x 1100 |
| Ask | 131.54 x 800 |
| Day's Range | 130.85 - 132.41 |
| 52 Week Range | 121.00 - 148.99 |
| Volume | 3,376,456 |
| Avg. Volume | 7,434,715 |
| Market Cap | 346.259B |
| Beta (3Y Monthly) | 0.72 |
| PE Ratio (TTM) | 21.79 |
| EPS (TTM) | 6.02 |
| Earnings Date | Oct 15, 2019 |
| Forward Dividend & Yield | 3.80 (2.91%) |
| Ex-Dividend Date | 2019-08-26 |
| 1y Target Est | 149.35 |
- Investor's Business Daily
Opioid Epidemic: Will Pharmas Scramble To Settle As Landmark Case Looms?
Endo International and Allergan could avoid going to trial in a landmark case out of Ohio accusing pharmaceutical companies of marketing practices that preceded the opioid epidemic.
- Reuters
Oklahoma judge to rule on Monday in opioid lawsuit against J&J
An Oklahoma judge will rule on Monday on whether Johnson & Johnson should be held liable in a lawsuit by the state's attorney general who argues the drugmaker should be forced to pay $17 billion for fueling the opioid epidemic. Judge Thad Balkman in Norman, Oklahoma, will deliver his decision from the bench after presiding over the first trial to result from thousands of lawsuits by state and local governments against opioid manufacturers and distributors, the court said. Opioids were involved in almost 400,000 overdose deaths from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention.
- InvestorPlace
3 Healthcare Stocks to Trade: UNH, JNJ and PFE
Even under normal circumstances, the healthcare stocks are prone to headline risk. Case in point, what happened to Sarepta (NASDAQ:SRPT) last night when the stock fell 15% on FDA news. Add to it that the U.S. is approaching another round of elections, and it makes healthcare stocks even riskier than normal -- through no fault of their own.In late June, I discussed three healthcare stocks to buy and for the most part the trades paid quickly. But since then, the stock markets in general had several mini corrections. We had fear flashes over geopolitical headlines, China's currency crisis and most recently, a bond-yield crash. So it's only fair to revisit those names again as the dust is settling. * 10 Undervalued Stocks With Breakout Potential So today we are discussing United Health (NYSE:UNH), Pfizer (NYSE:PFE), and Johnson & Johnson (NYSE:JNJ) stocks. I'll start with my conclusion first. All three are still good stocks to buy at these levels -- but for different reasons.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Johnson & Johnson (JNJ)Johnson & Johnson is a long-time American success story. They are a global household name and their products are ubiquitous. From a valuation perspective, JNJ stock is relatively cheap because it has a modest price-to-earnings (P/E) ratio and pays a decent dividend.JNJ could be cheaper, but this is a management team that has proven itself through thousands of headline worries. The current headlines are nothing new for JNJ. So they have nothing but a temporary effect on the overall trajectory of JNJ stock.That said, Johnson & Johnson is still a buy here for anyone who's looking to add this sector to their portfolio. It is important to note that the company is probably past its talcum-powder headline risk by now even though it's not officially resolved. So I wouldn't take a full position all at once. Alternatively, I can sell puts below the current JNJ stock price to generate income from the intrinsic value of JNJ stock this way I don't even need a rally to win. United Health (UNH)United Health stock has performed the best of the three healthcare stocks since my last write up. It had an immediate 9% spike so from a trading perspective that was good timing.In addition, the overall thesis on UNH stock since then has not changed. It is still trailing the S&P 500 year-to-date. But over the last five years, UNH stock is up 180%, which is four times better than the S&P.After the July spike, UNH stock price faded the rally, but is has fallen into the same support zone from which it broke out. So this is the opportunity for the bulls to rinse-and-repeat another run.Technically speaking, UNH range is tightening into a point, so a move is coming in either direction. It is setting lower-highs and higher-lows at a point that coincides with the 12 month point-of- control for the stock. This is significant because this is literally where bulls and bears have agreed the most.So they will fight it out hard at this price once more and create support. As long as UNH stock holds above $240 per share, the bulls have a shot at retesting $260 or higher. There will be resistance along the way perhaps at $255 and most certainly at $256.50. * 10 Mid-Cap Dividend Stocks to Buy Now Conversely, there is the threat that the bears are able to break below $240 per share. If that happens, it could turn into a bearish head-and-shoulder pattern to target $224 per share. This is not a forecast but it's definitely a scenario that exists currently below UNH stock price. Pfizer (PFE)Pfizer stock was once bulletproof, but it can't even find footing of late. But maybe this time will be different. From current levels Pfizer stock can mount a revenge rally. Clearly so far, its stock performance metrics are poor so this has a lot of hopium tied to it.So this is definitely a tactical trade, and it should have a hard stop below $34 per share. This inadvertently is also a long-term five-year-old pivot point that also happens to be the point of control for that same period. So mathematically speaking, this is where bulls and bears love to disagree. This congestion should act as support.Simply put, if I buy PFE stock here, I literally have more upside potential than downside risk based on the 5-year price history. Fundamentally speaking, PFE is not expensive selling at 17 P/E and three times book. Yes, it can get cheaper, but this trade set up is tactical, so fundamentals don't matter as much for the short term.Longer-term, the Pfizer management team needs to re-earn Wall Street trust so that trades like this one would be with conviction. Maybe then the bulls will be able to drag the PFE stock out of the dumps and back in line with the overall stock market or at least its sector.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. Join his live chat room for free here. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Dividend Stocks to Load Up On * The 10 Biggest Losers from Q2 Earnings * 5 Dependable Dividend Stocks to Buy The post 3 Healthcare Stocks to Trade: UNH, JNJ and PFE appeared first on InvestorPlace.
- Zacks
Quality ETFs for Volatile Markets
Stocks with excellent earnings growth and strong balance sheets deliver better risk adjusted returns over the long term
- Benzinga
'It's A Huge Thing': Avicanna Receives Unique Canadian Cannabinoid Research License
Health Canada has granted biopharmaceutical researcher and cannabis producer Avicanna Inc (TSX: AVCN) with a research license that will allow the company to perform research and intellectual property development on cannabinoids at its facility in the MaRS Discovery District in Toronto. It's a cannabis license, but for research and pharmaceutical development," CEO Aras Azadian told Benzinga in an interview.
- Zacks
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Johnson & Johnson, NVIDIA, Booking and Fidelity
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Johnson & Johnson, NVIDIA, Booking and Fidelity
- Motley Fool
Why Mallinckrodt and Endo International Shares Jumped Today
Investors appear to have some confidence that the companies will settle their opioid lawsuits.
- American City Business Journals
Jabil expected to earn $1B in fiscal 2020 off Johnson & Johnson deal
The St. Pete manufacturer was also issued a positive outlook on its new $1.8 billion commercial paper program.
- Zacks
Top Research Reports for Berkshire Hathaway, Johnson & Johnson & NVIDIA
Top Research Reports for Berkshire Hathaway, Johnson & Johnson & NVIDIA
- Investopedia
What Do AA+ and AAA Credit Ratings Mean?
Moody's just downgraded China's credit rating. So, what does it matter if you hold a AAA or AA+ rating?
- Investopedia
Top Defensive Consumer Stocks for 2018
These three defensive consumer stocks can add stability to your portfolio. These stocks deal with staples and are less susceptible to market volatility.
- Business Wire
JOHNSON & JOHNSON INVESTIGATION UPDATE by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Johnson & Johnson - JNJ
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (JNJ). The Company has been embroiled in significant litigation by over 11,000 consumers claiming that its iconic talc powder products contained asbestos that caused cancer. Some cases have resulted in massive verdicts against J&J including a $117 million award by one New Jersey jury in April 2018 and a $4.7 billion award in Missouri to 22 plaintiffs in July 2018.
- Moody's
Jabil Inc. -- Moody's assigns Prime-3 short term rating to Jabil's new $1.8 billion commercial paper program
Moody's Investors Service ("Moody's") assigned a Prime-3 short term rating to Jabil Inc.'s ("Jabil") new $1.8 billion commercial paper program. Borrowings under the new commercial paper program will be used to replace current revolver borrowings.
- Zacks
Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
FDA approves Roche's (RHHBY) tumor-agnostic medicine, Rozlytrek, J&J's Sirturo for young TB patients.
- InvestorPlace
10 Best Stocks to Buy and Hold Forever
[Editor's note: "10 Best Stocks to Buy and Hold Forever" was previously published in July 2019. It has since been updated to include the most relevant information available.]In a market environment that overwhelmingly encourages constant activity by investors who seemingly want to double their money every week, a discussion of stocks to buy and hold forever seems comically out of place.And yet, for better or worse, that's the mindset all of us should adopt when deploying most of our investing capital. More often than not, the more you trade, the worse you end up doing.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt has been said (and verified) that 95% of true "day traders" -- the most aggressive and active of all market participants -- end up losing money by being too active for their own good. Conversely, the fact that Warren Buffett's favorite holding period is "forever" and how he's got a track record most investors would envy is just as telling. * 10 Cheap Dividend Stocks to Load Up On With that as the backdrop, here's a rundown of 10 stocks to buy and hold forever … or at least until something significant changes with your life plans or the companies themselves. AT&T (T)Dividend Yield: 5.% Year-to-date gain: 20%Calling a spade a spade, shares of telecom giant AT&T Inc. (NYSE:T) haven't been easy to own in a while. The stock is down from its mid-2016 peak, while most other stocks are well up for the timeframe.Source: Shutterstock The impasse has been an increasingly-tougher wireless and broadband market. But now that it's acquired media outfit Time Warner Inc (NYSE:TWX), a turnaround might have begun.If your intended timeframe really is "forever" though, a tough couple of years is nothing … particularly considering you're collecting a healthy dividend yield on your position's current value.More than that though, this is a telco name with a lot of clout, and a little more than $50 billion in the bank. Alphabet (GOOGL, GOOG)Dividend Yield: N/A Year-to-date gain: 12.7%Fans and followers of the company will likely know that Google parent company Alphabet Inc (NASDAQ:GOOGL, NASDAQ:GOOG) beat Q4's earnings estimate, posting $12.77 per share.Source: Shutterstock What got lost in the shuffle is how operating margins fell to 21 % from last quarter's 24%.Appreciated or not, Alphabet is a profit and revenue growth machine that has earned its spot on a list of "forever" stocks to buy. It may not always beat estimates, but it does always increase its numbers. * 10 Cheap Dividend Stocks to Load Up On That's because it keeps finding a way to serve as the middleman for about 70% of web searches done on desktops, and boasts being the preferred search engine for about 90% of the queries made via a mobile device.If it was going to be toppled, we'd see evidence of it by now. 3M (MMM)Dividend Yield: 3.67% Year-to-date gain: -18%In an era where complicated companies are shedding disparate parts of themselves so each arm can be hyper-focused on doing one thing exceedingly well, 3M Co (NYSE:MMM) is something of an outlier.Source: Shutterstock It offers everything from office supplies to healthcare products to the power transformers you see perched on top of power-line poles.It's wild mix that seems to work for 3M though, giving the company something to sell regardless of the economic environment.The clincher: 3M has managed to pay and increase its dividend every year going all the way back to 1977. Walmart (WMT)Dividend Yield: 1.88% Year-to-date gain: 21%Yes, the advent of Amazon.com, Inc. (NASDAQ:AMZN) has proven problematic for the world's biggest retailer, Walmart Inc (NYSE:WMT).Source: Shutterstock Rumors of Walmart's death at the hands of Amazon, however, have been greatly exaggerated.After being knocked over a few years ago, the company has regrouped, having figured out a way to fight the ever-growing reach of its online rival. The evidence? Last quarter's revenue, excluding currency fluctuations, jumped 2.9%. * 10 Cheap Dividend Stocks to Load Up On While it has been an ugly battle at times, Walmart has finally learned how to compete with Amazon.com. The fact that it can leverage its stores to do so only bolsters the bullish case. Southern Co (SO)Dividend Yield: 4.49% Year-to-date gain: 30%No list of stocks to buy and hold forever would be complete without a utility stock. In good times and bad, consumers almost always pay their electricity bill.Source: Shutterstock And, even though margins are thin and power providers don't have a ton of pricing power, they have little competition in most markets. Most requests for rate hikes are also approved without question.To that end, Southern Co (NYSE:SO) is one of the top picks of the litter.Southern serves nine million customers, mostly in the south, although it's represented in most of the major regions of the United States. More important, Southern Co has dished out stunningly consistent (even if tiny) profit growth, setting the stage for equally consistent dividends. It has not failed to increase its annual payout since the late 90's. Johnson & Johnson (JNJ)Dividend Yield: 2.9% Year-to-date gain: 1.15%As advanced as we've become as a society, the need for medicines, surgical products and simple healthcare solutions like Band-Aids and Tylenol is never going to go away.Source: Shutterstock That means Johnson & Johnson (NYSE:JNJ) -- which maintains a bigger product portfolio than most investors realize -- will always have something to sell to someone.That being said, don't think for a minute that a play on J&J is capitulation in the search for respectable growth. The company isn't just about treating tummy troubles and selling no-tears baby shampoo. * 10 Cheap Dividend Stocks to Load Up On It still operates a pharmaceutical arm as well, with its pharma operational revenue jumping 4.4% year-over-year last quarter, Berkshire Hathaway (BRK.B, BRK.A)Dividend Yield: N/A Year-to-date gain: -2%If the Warren Buffett mindset is the underlying philosophy in play here, why not go straight to the source and buy a piece of the fund he built from the ground up? That's Berkshire Hathaway Inc. (NYSE:BRK.B, NYSE:BRK.A).Source: Shutterstock Sure, in his most recent letter to shareholders, the Oracle of Omaha said he's struggling to find new companies at a "sensible purchase price," which is the life-blood of the organization's growth. There's also the stark reality that the 87-year-old Buffett is increasingly less involved with Berkshire Hathaway. That separation is only going to widen as time marches on.Still, he has more than proven his way works for the long haul. Over the course of the past half-century, Berkshire stock has performed about twice as well as the S&P 500 has. Waste Management (WM)Dividend Yield: 1.73% Year-to-date gain: 33%There's an old adage … the only two sure things in life are death and taxes.Source: Shutterstock It's a humorous point about the limited nature of human life and the far-reaching power of the IRS. But, it's not necessarily a complete cliche. There's a third certainty. That is, as long as people are living on the planet earth, they'll be creating garbage to shuttle to their nearby landfill. Some of the best stocks to buy and hold are companies that haul that garbage away.Enter Waste Management, Inc. (NYSE:WM), which runs garbage-pickup services for 21 million North American customers. Although its top and bottom lines ebb and flow, the bigger trend for both is pointed upward. * 10 Cheap Dividend Stocks to Load Up On Look for more of the same too. As CEO Jim Fish pointed out last year, "The babyboomers are coming into a period of heavy medical spend. All of our parents are aging and spending more on medical spend. There is medical waste generated from that, we are in that business. The industrial economy is important to us.Whether it's through repatriation from the new tax law, or just through the fact the U.S. and Canada are great places to do business and the industrial economy is showing some signs of life, we are a big industrial player on the back-end of the cycle." American Water Works (AWK)Dividend Yield: 1.61% Year-to-date gain: 37.4%Perhaps just as certain as death, taxes and the creation of trash, as long as people are alive they're going to need water to survive. That puts a water utility name like American Water Works Company Inc (NYSE:AWK) in the catbird seat. Reliability and demand make water utilities safe stocks to buy when others seem sketchy.Source: Shutterstock Much like electricity providers Southern Company, American Water Works Company -- which offers water and sewer services to 15 million people in the United States -- is rarely told no when it wants to raise rates.Water service prices have risen at above-inflation rates for the past several years, and American Water Works Company has benefited from that industry-wide trend. It's not apt to change anytime soon. Colgate-Palmolive (CL)Dividend Yield: 2.40% Year-to-date gain: 21%Last but not least, while the purchase of things like cars are cyclical, and the automobile industry itself is subject to constant reinvention, there are some consumer goods people just buy over and over again without a second thought. When it comes to the best stocks to buy and hold, you just can't forget consumer staples.Source: Shutterstock Among those often-repurchased items are Colgate toothpaste, Palmolive dish soap, Speed Stick deodorant and Cuddly fabric conditioner.Yep, they're all made by Colgate-Palmolive Company (NYSE:CL), though they're only a small sampling of the brands you'll find under the company's umbrella. * 10 Cheap Dividend Stocks to Load Up On Those who know the Colgate-Palmolive story well will know the company has gotten into some sloppy spending habits, crimping margins more than most shareholders would like. That's starting to change, however, with a serious and rather impressive cost-cutting initiative. The benefits of that work could last years, if not decades.As of this writing, James Brumley hold a long position in AT&T. You can follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy for June * 7 Stocks to Buy From One of America's Best Pension Funds * 4 Consumer Staples Stocks for Both Income and Growth The post 10 Best Stocks to Buy and Hold Forever appeared first on InvestorPlace.
- Yahoo Finance
These are the largest companies in each U.S. state
Do you know what the largest company is in your state?
- Investopedia
The Top Pharma Stocks for 2019
Find out how the pharmaceutical industry is thriving, the new drugs that are coming to market, and the top pharmaceutical stocks for 2019.
- Zacks
Why Is Johnson & Johnson (JNJ) Down 1.2% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study
Lilly's (LLY) Taltz is an important revenue driver for Lilly. Top-line data from a study shows that Taltz helps more plaque psoriasis patients achieve 100% skin clearance compared to Tremfya.
- InvestorPlace
JNJ Stock Is a Way Better Investment Than Bonds or CDs
Johnson & Johnson (NYSE:JNJ) is not the world's most exciting stock, and it's been a fairly underwhelming past two years even by J&J standards. Two years ago, JNJ stock was trading around $130 per share. It's back there again today.Source: Shutterstock JNJ stock has underperformed the market recently on a variety of short-term worries. These include its potential liabilities in various product lawsuits, weak drug pricing, and regulatory and political concerns.In the long run, however, the stock's short-term weakness could be setting up an opportunity. Because while shares have stalled out, Johnson and Johnson's dividends go up every year. That's in stark contrast to interest rates, which are plummeting again.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Interest Rates Are Going to Zero, And BeyondThere seems to be almost no limit to how low bond yields can go. In the United States, long-term treasury yields have plummeted back to their lowest levels in decades. * 7 Stocks the Insiders Are Buying on Sale The 10-year treasury yield, for example, hit 1.5% in 2016. That appeared to be a generational low - in 2017 rates soared as investors factored in more growth and inflation from President Trump's Administration. This never panned out however, and the 10-year yield has plunged back to the 2016 lows.Overseas, it's even more dramatic. All told, the world has roughly $15 trillion in debt that has a negative yield. That means that you buy these bonds today, you'll get less back through maturity than you pay upfront. You literally would get better returns putting money in your mattress.The madness doesn't stop there. Some European junk bonds (that is, companies with poor credit) now have negative-yielding bonds. Even companies with flimsy balance sheets now get to borrow for free or next to nothing. On the flip side of the coin, we just heard about a European bank that will start offering negative interest mortgages. In English, that means that homeowners will be paid to take out a mortgage. J&J Faces Short-Term HeadwindsWith all that in mind, it's worth taking another look at high-quality blue-chip stocks like Johnson and Johnson. Not everything is going perfectly for Johnson and Johnson right now.Read my previous article about the company, which discusses its exposure to liability lawsuits, among other things, for more perspective.And I stand by that call. If you are a short-term trader, this isn't a great time to pick up JNJ stock. The company faces short-term challenges from lawsuits, pressure on drug pricing, and potentially harmful changes to the health care regulatory structure in the U.S. It's not all blue skies for Johnson and Johnson at this very moment. Johnson and Johnson Is a Health Care TitanHowever, if you are looking at JNJ stock as an alternative to bonds or other fixed income, the situation changes dramatically. As I said in my article on Johnson and Johnson's opioid and talc issues, that's a short-term headwind for JNJ stock. But the long-term picture remains extremely bright.J&J is a highly diversified company. In effect, it runs as a conglomerate, giving its independent brands and divisions plenty of room to manage their own affairs. This greatly reduces risk, as any single product or drug's sales don't pose much risk to the overall franchise.On a bigger level, J&J operates in three main segments. They have consumer products for things such as baby and skincare. They have medical devices. And they have pharmaceutical drugs.The huge range of products and different needs that J&J serves greatly protects the company from competition, economic downturns, and specific government regulation. For more than a century, Johnson and Johnson has prospered through numerous depressions and world wars. Fixed Income Isn't Paying Very Much Right NowOver the next three months or even a year, anything can happen. If you hold Johnson and Johnson as a long-term investment in place of bonds, CDs, or other fixed-income products, however, the odds are skewed highly in your favor.Let's look at two concrete examples. First, what happens if you buy an FDIC-insured bank CD right now? As of this writing, the highest CD rate available on a five-year term from a nationally-known bank is 2.65% from Goldman Sachs (NYSE:GS). Give their bank $1,000 and you'll get back a guaranteed $26.50 every year for the next five years, or $132.50 in total interest, plus your $1,000 of principle.Now let's turn to five-year government treasury bonds. These are not insured by the FDIC, but are backed by the full faith and credit of the U.S. government, which is still highly rated despite its flaws. At this time, five-year treasury bonds yield 1.5%. Buy $1,000 of one of these bonds, and hold to maturity, and you'll get your $1,000 back plus $15 annually in interest. That'd be $75 total. Not as good as the Goldman Sachs bank CD. JNJ Stock Will Crush Bonds If You're PatientJNJ stock, on the other hand, is currently yielding 2.9%. Invest $1,000 in it, and you'll get back $7.25 every three months, or $29 annually. If nothing changed, you'd get back $145 in dividends over the next five years, comfortably beating the bank CD at $132 and the government bond at $75. But things get better. Historically, Johnson and Johnson raises its dividend by about 7% every year.This means that while you're getting $29 of dividends from Johnson and Johnson stock this year, by the fifth year, you'd be getting $41 annually. Over time, the numbers continue to grow.Had you bought JNJ stock a decade ago, it'd be paying back nearly 10% of your initial investment annually. Bonds and CDs, however, never see their yields go up over time. Also, while nothing is guaranteed, more often than not, JNJ stock will appreciate in value, giving you a capital gain in addition to your rising dividend yield.In a world where interest rates are going lower and lower, Johnson and Johnson stock looks like a fantastic bond alternative. At its relatively high valuation and with the lawsuit overhang, is the stock going to crush the market over the next year or two? Probably not. Will it beat fixed income investments over the next five, ten, or twenty years? There's a great likelihood that it will.At the time of this writing, Ian Bezek owned JNJ stock and GS stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 The post JNJ Stock Is a Way Better Investment Than Bonds or CDs appeared first on InvestorPlace.
- Benzinga
Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study
Lilly said Tuesday ahead of the market open that Talz, a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine, met the primary and all major secondary endpoints up to 12 weeks in the Phase 4 IXORA-R study. Taltz has been approved for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and also for adults with psoriatic arthritis.
- Simply Wall St.
What Kind Of Shareholders Own Johnson & Johnson (NYSE:JNJ)?
Every investor in Johnson & Johnson (NYSE:JNJ) should be aware of the most powerful shareholder groups. Institutions...
- Motley Fool
5 Biggest New Drugs Approved in 2019 So Far
And the one big pharma most likely to benefit the most.
- Investor's Business Daily
Dow Jones Falls 300 Points; Pfizer, Goldman Sachs Lead Downside
The Dow Jones led the downside Monday, weighed down by weakness in Pfizer and Goldman Sachs, but several stocks in the MarketSmith Growth 250 outperformed.
- Motley Fool
The 10 Biggest Value Stocks
If you want to get started with value investing, take a look at these massive companies.
